BR112021023483A2 - Novo anticorpo anti-vírus da hepatite b e seus usos - Google Patents

Novo anticorpo anti-vírus da hepatite b e seus usos

Info

Publication number
BR112021023483A2
BR112021023483A2 BR112021023483A BR112021023483A BR112021023483A2 BR 112021023483 A2 BR112021023483 A2 BR 112021023483A2 BR 112021023483 A BR112021023483 A BR 112021023483A BR 112021023483 A BR112021023483 A BR 112021023483A BR 112021023483 A2 BR112021023483 A2 BR 112021023483A2
Authority
BR
Brazil
Prior art keywords
hbv
hepatitis
antibodies
hbsag
subject
Prior art date
Application number
BR112021023483A
Other languages
English (en)
Inventor
Can Wen
Jixian Tang
Ningshao Xia
Quan Yuan
Tianying Zhang
Wenxin Luo
Xinchu Xiang
Yangtao Wu
Original Assignee
Univ Xiamen
Yang Sheng Tang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Xiamen, Yang Sheng Tang Co Ltd filed Critical Univ Xiamen
Publication of BR112021023483A2 publication Critical patent/BR112021023483A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

novo anticorpo anti-vírus da hepatite b e seus usos. são divulgados anticorpos para o antígeno de superfície anti-hepatite b (hbsag) (especialmente anticorpos humanizados), moléculas de ácidos nucleicos que codificam os mesmos, métodos para preparar os mesmos e composições farmacêuticas contendo os mesmos. os anticorpos têm maior afinidade para hbsag em ph neutro do que em ph ácido, aumentando, desse modo, significativamente a eficiência de eliminação do vírus e prolongando o tempo de inibição do vírus. os anticorpos e as composições farmacêuticas podem ser usados para prevenir e/ou tratar infecções por hbv ou doenças relacionadas a infecções por hbv (por exemplo, hepatite b), para neutralizar a virulência do hbv em um sujeito (por exemplo, um humano), para reduzir o nível sérico de dna de hbv e/ou hbsag no corpo do sujeito, ou para ativar a resposta imune humoral do sujeito (por exemplo, um infectado crônico por hbv ou paciente com hepatite b crônica) contra o vhb.
BR112021023483A 2019-05-23 2020-05-22 Novo anticorpo anti-vírus da hepatite b e seus usos BR112021023483A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910432602 2019-05-23
PCT/CN2020/091739 WO2020233695A1 (zh) 2019-05-23 2020-05-22 抗乙肝病毒新型抗体及其用途

Publications (1)

Publication Number Publication Date
BR112021023483A2 true BR112021023483A2 (pt) 2022-02-08

Family

ID=73441881

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021023483A BR112021023483A2 (pt) 2019-05-23 2020-05-22 Novo anticorpo anti-vírus da hepatite b e seus usos
BR112021023485A BR112021023485A2 (pt) 2019-05-23 2020-05-22 Anticorpos anti-vírus da hepatite b e uso dos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112021023485A BR112021023485A2 (pt) 2019-05-23 2020-05-22 Anticorpos anti-vírus da hepatite b e uso dos mesmos

Country Status (9)

Country Link
US (2) US20220251173A1 (pt)
EP (2) EP3974446A4 (pt)
JP (2) JP2022534080A (pt)
KR (2) KR20220012297A (pt)
CN (2) CN111978392B (pt)
AU (2) AU2020280543A1 (pt)
BR (2) BR112021023483A2 (pt)
CA (2) CA3141648A1 (pt)
WO (2) WO2020233715A1 (pt)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2000253878A (ja) * 1999-03-09 2000-09-19 Nisshinbo Ind Inc ヒト抗ＨＢｓ抗体
PL2275443T3 (pl) 2008-04-11 2016-05-31 Chugai Pharmaceutical Co Ltd Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
SG174401A1 (en) 2009-03-31 2011-11-28 Oridis Biomarkers Gmbh Method for diagnosis of cancer and monitoring of cancer treatments
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
KR102239138B1 (ko) 2011-09-30 2021-04-12 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
KR101944263B1 (ko) * 2012-06-11 2019-02-01 시아먼 유니버시티 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체
CN107001429B (zh) 2014-11-28 2022-01-04 赛特瑞恩股份有限公司 乙型肝炎病毒表面抗原的表位及与其特异性结合以中和乙型肝炎病毒的结合分子
CN106480070B (zh) * 2015-08-25 2023-10-20 厦门大学 一种用于展示目的多肽的多肽载体及其用途
EP3360896A4 (en) * 2015-10-09 2019-08-28 Xiamen University ANTIBODIES TO HEPATITIS B SURFACE ANTIGEN AND USE THEREOF
US11324819B2 (en) * 2016-04-06 2022-05-10 University Of Washington Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen
WO2018052556A1 (en) * 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
KR102358577B1 (ko) * 2017-02-17 2022-02-04 시아먼 유니버시티 타겟 폴리펩티드를 제시하는 펩티드 캐리어 및 이의 용도
KR20200010217A (ko) * 2017-04-07 2020-01-30 시아먼 유니버시티 Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체
SG11201909572QA (en) * 2017-04-18 2019-11-28 Alnylam Pharmaceuticals Inc Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
GB201707484D0 (en) * 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies

Also Published As

Publication number Publication date
JP2022534080A (ja) 2022-07-27
KR20220012297A (ko) 2022-02-03
AU2020280539A1 (en) 2022-01-27
JP2022542743A (ja) 2022-10-07
EP3981786A4 (en) 2023-07-26
AU2020280543A1 (en) 2022-01-27
CN111978393A (zh) 2020-11-24
EP3974446A4 (en) 2023-08-02
BR112021023485A2 (pt) 2022-02-08
CA3141648A1 (en) 2020-11-26
CA3141673A1 (en) 2020-11-26
JP7372638B2 (ja) 2023-11-01
WO2020233715A1 (zh) 2020-11-26
EP3981786A1 (en) 2022-04-13
CN111978393B (zh) 2024-06-18
US20220251173A1 (en) 2022-08-11
KR20220012338A (ko) 2022-02-03
US20220235117A1 (en) 2022-07-28
WO2020233695A1 (zh) 2020-11-26
CN111978392A (zh) 2020-11-24
CN111978392B (zh) 2024-05-24
EP3974446A1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
BRPI0212999B1 (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
BRPI0509079A (pt) molécula de ácido nucléico, vetor, célula hospedeira, partìculas tipo vìrus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
Lampertico et al. Add‐on peginterferon alfa‐2a to nucleos (t) ide analogue therapy for Caucasian patients with hepatitis B ‘e’antigen‐negative chronic hepatitis B genotype D
CN103386128B (zh) 一种含联合佐剂的结核亚单位疫苗
TWI781088B (zh) 包含固定化病毒粒子之疫苗
BR112022010425A2 (pt) Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
BR112018007121A2 (pt) anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv
Casey et al. Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks
Yoshida et al. Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study
Pentón-Arias et al. Cuban prophylactic and therapeutic vaccines for controlling hepatitis B
Foster et al. Effect of antiviral treatment with entecavir on age-and dose-related outcomes of duck hepatitis B virus infection
RU2008151516A (ru) СПОСОБ УВЕЛИЧЕНИЯ БИОЛОГИЧЕСКОЙ АКТИВНОСТИ ОЧИЩЕННОГО БЕЛКА HspE7
BR112021023483A2 (pt) Novo anticorpo anti-vírus da hepatite b e seus usos
Lelie et al. Immune Response to a Heat-Inactivated Hepatitis B Vaccine in Patients Undergoing Hemodialysis: Enhancement of the Response by Increasing the Dose of Hepatitis B Surface Antigen From 3 to 27 µg
Tamura et al. pp60c-src is a substrate for phosphorylation when cells are stimulated to enter cycle
Howard et al. Preparation and properties of immune-stimulating complexes containing hepatitis B virus surface antigen
Simmons et al. Relationship between the methionine tryptic peptides of simian virus 40 and BK virus tumor antigens
Shibuya et al. Murine cross-reactive nonneutralizing polyclonal IgG1 antibodies induced by influenza vaccine inhibit the cross-protective effect of IgG2 against heterologous virus in mice
Wu et al. Novel approaches towards conquering hepatitis B virus infection
CN102241744B (zh) 一种病毒感染阻断剂、其药物组合物及其应用
Enomoto et al. High phosphorylation of HBV core protein by two α-type CK2-activated cAMP-dependent protein kinases in vitro
Munir et al. Crimean-Congo hemorrhagic fever: Immunopathogenesis and recent advances in the development of vaccines
Bull et al. Early vaccine‐mediated strain‐specific cytokine imbalance induces mild immunopathology during influenza infection
Revill et al. The basis for antiviral therapy: Drug targets, cross-resistance, and novel small molecule inhibitors
BR9908540A (pt) Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c